Evidence-Based Oncology > Peer Exchange: Spring 2017 Oncology Stakeholders Summit
Evidence-Based Oncology – Peer Exchange: Spring 2017 Oncology Stakeholders Summit
May 17, 2017 – Surabhi Dangi-Garimella, PhD
At the The American Journal of Managed CareÂ®'s Spring 2017 Oncology Stakeholders Summit, the discussion touched off-label communication, the evolving clinical trial design, and healthcare reform, all while ensuring care is patient-centered.
May 18, 2017 – Surabhi Dangi-Garimella, PhD
An interview with Daryl Pritchard, PhD, vice president for Science Policy at the Personalized Medicine Coalition, on the FDA's drug approval process, developments in the personalized medicine field, and reimbursement models that integrate diagnostics.
May 17, 2017 – David M. Rind, MD; and Sarah K. Emond, MPP
The Institute for Clinical and Economic Review (ICER), has established a robust health technology assessment strategy for engaging patients so that the entire process is informed by the patient experience and what “value” means to them.
FDA Oncology Center of Excellence Moves Forward on Coordinated Clinical Reviews, Integrated Approach to the Clinical Evaluation of Oncology Products
May 17, 2017 – Richard Pazdur, MD
An overview of the FDA's Oncology Center of Excellence-a collaborative approach to the clinical approval process.
May 16, 2017 – John Peabody, MD, PhD, FACP
It is a fundamental premise that providers and health systems who want to succeed in the existing uncertain healthcare environment must remain focused on delivering value-the highest-quality care at the most efficient price.